INNATE PHARMA SA-SPONS ADR (IPHA) Forecast, Price Target & Analyst Ratings
NASDAQ:IPHA • US45781K2042
1.58 USD
-0.07 (-4.24%)
Last: Mar 3, 2026, 08:20 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INNATE PHARMA SA-SPONS ADR (IPHA).
Forecast Snapshot
Consensus Price Target
$7.41
+ 368.75% Upside
Next Earnings Forecast
Release DateMar 26, 2026
PeriodQ3 / 2025
EPS Estimate-€0.11
Revenue Estimate1.98M
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.41
Upside
+ 368.75%
From current price of $1.58 to mean target of $7.41, Based on 8 analyst forecasts
Low
$7.27
Median
$7.41
High
$7.69
Price Target Revisions
1 Month
0.68%
3 Months
30.64%
Price Target Summary
8 analysts have analysed IPHA and the average price target is 7.41 USD. This implies a price increase of 368.75% is expected in the next year compared to the current price of 1.58.
The average price target has been revised upward by 30.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
IPHA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IPHA.
In the previous month the buy percentage consensus was at a similar level.
IPHA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-29 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-29 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-09-18 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-09-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | SVB Leerink | Maintains | Outperform |
| 2022-09-16 | Citigroup | Maintains | Buy |
| 2022-08-02 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2021-09-17 | SVB Leerink | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 26, 2026
PeriodQ3 / 2025
EPS Estimate-€0.11
Revenue Estimate1.98M
Revenue Q2QN/A
EPS Q2QN/A
Number of Analysts2
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.01%
EPS (3 Months)
1.64%
Next Earnings Summary
IPHA is expected to report earnings on 3/26/2026. The consensus EPS estimate for the next earnings is -0.11 USD and the consensus revenue estimate is 1.98M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 49.58M 309.35% | 51.901M 4.68% | 12.622M -75.68% | 25.818M 104.55% | 25.319M -1.93% | 15.809M -37.56% | 64.861M 310.28% | 192.15M 196.25% | 169.64M -11.71% | 219.94M 29.65% | 258.83M 17.68% | 440.9M 70.34% | |
| EBITDA YoY % growth | 28.98M 167.04% | -7.578M -126.15% | -49.581M -554.28% | 27.27M 155.00% | 144.43M 429.63% | 192.91M 33.57% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.425M 65.66% | -12.669M 22.87% | -51.575M -307.10% | -15.288M 70.36% | 34.614M 326.41% | -61.384M -277.34% | -65.419M -6.57% | 41.243M 163.04% | 64.201M 55.67% | 103.81M 61.70% | 132.25M 27.40% | N/A | |
| Operating Margin | -33.13% | -24.41% | -408.61% | -59.21% | 136.71% | -388.28% | -100.86% | 21.46% | 37.85% | 47.20% | 51.10% | N/A | |
| EPS YoY % growth | N/A 72.93% | N/A -169.82% | N/A 23.22% | -0.52 -35.80% | -0.46 10.00% | -0.64 -38.38% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 | -0.11 | -0.11 -9.09% | -0.07 72.00% | -0.12 -8.33% | -0.09 16.67% | -0.12 -8.33% | -0.12 -85.71% | -0.08 30.77% | -0.12 -30.00% |
| Revenue Q2Q % growth | 1.98M | 2.172M -49.83% | 2.222M -54.35% | 7.817M 367.80% | 2.293M 15.81% | 2.404M 10.68% | 2.353M 5.90% | 2.788M -64.33% | 9.878M 330.79% | 6.989M 190.72% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.857M | -12.665M 49.86% | -13.019M -34.83% | -8.211M 67.71% | -13.645M -6.13% | -16.17M -27.67% | -19.766M -51.82% | -19.443M -136.78% | -14.685M -7.62% | -19.917M -23.17% |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-19.15%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-22.02%
Revenue Next 5 Year
41.95%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
95.79%
EBIT Next 5 Year
N/A
INNATE PHARMA SA-SPONS ADR / IPHA Forecast FAQ
What is the average price target for INNATE PHARMA SA-SPONS ADR (IPHA) stock?
8 analysts have analysed IPHA and the average price target is 7.41 USD. This implies a price increase of 368.75% is expected in the next year compared to the current price of 1.58.
Can you provide the upcoming earnings date for INNATE PHARMA SA-SPONS ADR?
INNATE PHARMA SA-SPONS ADR (IPHA) will report earnings on 2026-03-26, after the market close.
What are the consensus estimates for IPHA stock next earnings?
The consensus EPS estimate for the next earnings of INNATE PHARMA SA-SPONS ADR (IPHA) is -0.11 USD and the consensus revenue estimate is 1.98M USD.
How do analysts rate INNATE PHARMA SA-SPONS ADR (IPHA)?
The consensus rating for INNATE PHARMA SA-SPONS ADR (IPHA) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.